In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2
Open Access
- 3 June 2014
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 7, 51
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a complex, multidomain protein which is considered a valuable target for potential disease-modifying therapeutic strategies for Parkinson’s disease. In mammalian cells and brain, LRRK2 is phosphorylated and treatment of cells with inhibitors of LRRK2 kinase activity can induce LRRK2 dephosphorylation at a cluster of serines including Ser910/935/955/973. It has been suggested that phosphorylation levels at these sites reflect LRRK2 kinase activity, however kinase-dead variants of LRRK2 or kinase activating variants do not display altered Ser935 phosphorylation levels compared to wild type. Furthermore, Ser910/935/955/973 are not autophosphorylation sites, therefore, it is unclear if inhibitor induced dephosphorylation depends on the activity of compounds on LRRK2 or on yet to be identified upstream kinases. Here we used a panel of 160 ATP competitive and cell permeable kinase inhibitors directed against all branches of the kinome and tested their activity on LRRK2 in vitro using a peptide-substrate-based kinase assay. In neuronal SH-SY5Y cells overexpressing LRRK2 we used compound-induced dephosphorylation of Ser935 as readout. In silico docking of selected compounds was performed using a modelled LRRK2 kinase structure. Receiver operating characteristic plots demonstrated that the obtained docking scores to the LRRK2 ATP binding site correlated with in vitro and cellular compound activity. We also found that in vitro potency showed a high degree of correlation to cellular compound induced LRRK2 dephosphorylation activity across multiple compound classes. Therefore, acute LRRK2 dephosphorylation at Ser935 in inhibitor treated cells results from compound activity on the LRRK2 ATP-binding pocket itself. Understanding the regulation of LRRK2 phosphorylation by kinase inhibitors aids our understanding of LRRK2 signaling and may lead to development of new classes of LRRK2 kinase inhibitors.Keywords
This publication has 56 references indexed in Scilit:
- Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylationJournal of Pharmaceutical and Biomedical Analysis, 2013
- Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)Expert Opinion on Therapeutic Patents, 2012
- Biochemical Characterization of Highly Purified Leucine-Rich Repeat Kinases 1 and 2 Demonstrates Formation of HomodimersPLOS ONE, 2012
- Brain Penetrant LRRK2 InhibitorACS Medicinal Chemistry Letters, 2012
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's diseaseNature Reviews Neuroscience, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- Determination of a large number of kinase activities using peptide substrates, P81 phosphocellulose paper arrays and phosphor imagingAnalytical Biochemistry, 2003
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000